GIMBE - AME 2003


	Associazione Medici Endocrinologi	III Congresso Nazionale AME Palermo, 7-9 novembre 2003

Workshop Clinici Interattivi Chairman: Antonino Cartabellotta
Alcuni degli articoli non disponibili in full text possono essere richiesti a: segreteria@gimbe.org Per visualizzare le diapositive è necesssario Acrobat Reader
Introduzione
Slides
Sindrome Metabolica DIscussant: Stefano Del Prato (Pisa) Paolo Moghetti (Verona)
Slides Evidence appraised Linee guida National Heart, Blood and Lung Institute. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) American Association of Clinical Endocrinologist. AACE Position: Insulin Resistance Syndrome American Diabetes Association. Clinical Practice Recommendations 2003. Management of Dyslipidemia in Adults With Diabetes American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee, American Heart Association Diabetes Committee. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation. 2003 Mar 18;107(10):1448-53 Revisioni sistematiche Nessuna Revisioni narrative, editoriali Shaw JE, Chisholm DJ. Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust. 2003 Oct 6;179(7):379-83. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation. 2003 Sep 30;108(13):1552-3 Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003 Sep 30;108(13):1546-51 Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003 Sep 30;108(13):1541-5. Wilson PW, Grundy SM. The Metabolic Syndrome: Practical Guide to Origins and Treatment: Part I. Circulation 2003;108:1422-1424 Wilson PW, Grundy SM. The Metabolic Syndrome: A Practical Guide to Origins and Treatment: Part II. Circulation 2003;108:1537-1540 Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol. 2003 Jul 3;92(1A):35i-42i. Meigs JB. The metabolic syndrome. BMJ 2003;327:61-2 Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol. 2003 Apr 3;91(7A):29E-39E. [abstract] Hill JO, Bessesen D. What to do about the metabolic syndrome? Arch Intern Med 2003;163:395-7 Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-8 Bloomgarden ZT. Obesity, hypertension, and insulin resistance. Diabetes Care. 2002 Nov;25(11):2088-97. Vega GL. Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity, the metabolic syndrome, and cardiovascular disease. Am Heart J 2001 Dec;142(6):1108-16. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 2001 Dec 13;414(6865):821-7. [abstract] Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol. 2000 Jun;16(6):779-89 [abstract] Hansen BC. The metabolic syndrome X. Ann N Y Acad Sci. 1999 Nov 18;892:1-24 Ricerca primaria Studi osservazionali C. Lorenzo, M. Okoloise, K. Williams, et al. The Metabolic Syndrome as Predictor of Type 2 Diabetes: The San Antonio Heart Study. Diabetes Care 2003;26:3153-3159. Meigs JB, Wilson PW, Nathan DM, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003 Aug;52(8):2160-7. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003 Feb 24;163(4):427-36. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes mellitus, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-214 Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16 Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070-1077. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med. 2002 Oct 14;162(18):2074-9. Deedwania PC. Clinical significance of cardiovascular dysmetabolic syndrome. Curr Control Trials Cardiovasc Med 2002;3:2 Isomaa B, Almgren P, Tuomi T, et al Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689 Trial clinici Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350
Trattamento della Menopausa DIscussant: Angela Maria Becorpi (Firenze), Domenico Gullo (Palermo)
Slides Evidence appraised Linee guida Agenzia Sanitaria per i Servizi Regionali. Linee guida sulla Menopausa (in corso di pubblicazione) U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale, 2002 North American Menopause Society Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause. 2003 Mar-Apr;10(2):113-32. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003;10:6-12 The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. Menopause 2000;7:215-229 Prodigy (UK). Menopause, 2002 Society of Obstetricians and Gynaecologists of Canada. The Canadian Consensus Conference on Menopause and Osteoporosis, 2002 New Zealand Guidelines Group. Best practice evidence-based guideline for the appropriate prescribing of hormone replacement therapy, 2001 (Update 2002) American Association of Clinical Endocrinologists AACE Position: Women’s Health Initiative AACE medical guidelines for clinical practice for management of menopause, 1999 American College of Preventive Medicine. Practice Policy Statement Perimenopausal and Postmenopausal Hormone Replacement Therapy, 1999 Evidence summaries Clinical Evidence, ottobre 2003 Technology assessment Agency for Healthcare Research and Quality (AHRQ), 2002. Hormone Replacement Therapy, 2002 Swedish Council on Technology Assessment in Health Care. Hormone replacement therapy Revisioni sistematiche Cochrane MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd. Lethaby A, Farquhar C, Sarkis A, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd. Non-Cochrane Mishra SI, Dickerson V, Najm W. Phytoestrogens and breast cancer prevention: what is the evidence? Am J Obstet Gynecol. 2003 May;188(5 Suppl):S66-70. [abstract] Brewer D, Nashelsky J. What non-hormonal therapies are effective for postmenopausal vasomotor symptoms? J Fam Pract 2003;52:324-5 Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002 Sep 21;360(9337):942-4. Nelson HD, Humphrey LL, Nygren P, et al Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002 Aug 21;288(7):872-81 Kronenberg F, Fugh-Berman A.Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137:805-13 Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002 Aug 20;137(4):273-84. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2002 May 7;136(9):680-90. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002 Jan;87(1):16-23. Revisioni non sistematiche Brewer D, Nashelsky J. What non-hormonal therapies are effective for postmenopausal vasomotor symptoms? J Fam Pract 2003;52:324-5 Humphries KH, Gill S. Risks and benefits of hormone replacement therapy: the evidence speaks. CMAJ 2003;168:1001-10 Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ 2003 Feb 8;326(7384):322-6 Editoriali Bailar J. Hormone-replacement therapy and cardiovascular diseases. N Engl J Med 2003;349:521-2 Herrington DM, Howard TD. From presumed benefit to potential harm--hormone therapy and heart disease. N Engl J Med. 2003;349:519-21 Grady D. Postmenopausal hormones--therapy for symptoms only. N Engl J Med 2003;348:1835-7 Yusuf S, Anand S. Hormone replacement therapy: a time for pause. CMAJ 2002;167:357-9 Sackett DL. The arrogance of preventive medicine. CMAJ 2002;167:363-364 Ricerca primaria (RCTs ed altri studi) Women's Health Initiative (WHI) Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34 Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48 Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003 Oct 1;290(13):1729-38. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003 Jun 25;289(24):3243-53 Wassertheil-Smoller S, Hendrix SL, Limacher M, wt al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003 May 28;289(20):2673-84 Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003 May 28;289(20):2663-72 Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28;289(20):2651-62 ABSTRACT Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54 Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. HERS Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) JAMA 2002;288:58-64. Grady D, Herrington D, Bittner V, et al. Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) JAMA 2002;288:49-57 Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13 Altri trial Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003;290:207-14 Studi osservazionali Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27